ATE334120T1 - Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems - Google Patents

Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems

Info

Publication number
ATE334120T1
ATE334120T1 AT95944268T AT95944268T ATE334120T1 AT E334120 T1 ATE334120 T1 AT E334120T1 AT 95944268 T AT95944268 T AT 95944268T AT 95944268 T AT95944268 T AT 95944268T AT E334120 T1 ATE334120 T1 AT E334120T1
Authority
AT
Austria
Prior art keywords
amine
butene
methyl
nervous system
central nervous
Prior art date
Application number
AT95944268T
Other languages
English (en)
Inventor
Merouane Bencherif
Patrick Michael Lippiello
William Scott Caldwell
Gary Maurice Dull
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/364,977 external-priority patent/US5824692A/en
Priority claimed from US08/364,978 external-priority patent/US5731314A/en
Priority claimed from US08/364,979 external-priority patent/US5597919A/en
Application filed by Targacept Inc filed Critical Targacept Inc
Application granted granted Critical
Publication of ATE334120T1 publication Critical patent/ATE334120T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
AT95944268T 1995-01-06 1995-12-28 Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems ATE334120T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/364,977 US5824692A (en) 1995-01-06 1995-01-06 Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US08/364,978 US5731314A (en) 1995-01-06 1995-01-06 Pharamceutical compositions for prevention and treatment of tourette's syndrome
US08/364,979 US5597919A (en) 1995-01-06 1995-01-06 Pyrimidinyl or Pyridinyl alkenyl amine compounds

Publications (1)

Publication Number Publication Date
ATE334120T1 true ATE334120T1 (de) 2006-08-15

Family

ID=27408680

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95944268T ATE334120T1 (de) 1995-01-06 1995-12-28 Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems

Country Status (6)

Country Link
EP (1) EP0801527B1 (de)
JP (1) JP3899126B2 (de)
AT (1) ATE334120T1 (de)
AU (1) AU4610896A (de)
DE (1) DE69535131T2 (de)
WO (1) WO1996020600A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616707A (en) * 1995-01-06 1997-04-01 Crooks; Peter A. Compounds which are useful for prevention and treatment of central nervous system disorders
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
US6979695B2 (en) 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
DK0900200T5 (da) 1996-04-23 2010-01-11 Targacept Inc Farmaceutiske sammensætninger til forebyggelse og behandling af sygdom i centralnervesystemet
US20020052497A1 (en) 2000-03-09 2002-05-02 Targacept, Inc. Compounds capable of activating cholinergic receptors
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5811442A (en) * 1997-02-21 1998-09-22 Bencherif; Merouane Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow
EP0973743B1 (de) * 1997-02-21 2004-08-25 Targacept, Inc. Pharmazeutische zusammensetzungen welche aryl-substituierte olefinische amin-verbindungen enthalten
US5861423A (en) 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US6531606B1 (en) 1997-02-21 2003-03-11 Targacept, Inc. Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US6232316B1 (en) 1998-06-16 2001-05-15 Targacept, Inc. Methods for treatment of CNS disorders
US7790757B2 (en) 1998-06-16 2010-09-07 Targacept, Inc. Compounds capable of activating cholinergic receptors
AU4230799A (en) * 1998-06-16 2000-01-05 Targacept, Inc. Aryl substituted olefinic amines and their use as cholinergic receptors agonists
US20050131034A1 (en) 1998-06-16 2005-06-16 Caldwell William S. Compounds capable of activating cholinergic receptors
AU5326100A (en) * 1999-06-07 2000-12-28 Targacept, Inc. Pharmaceutical compositions and methods for use
AU780009B2 (en) * 1999-08-31 2005-02-24 Merck Sharp & Dohme Corp. Heterocyclic compounds and methods of use thereof
AU2001257449A1 (en) * 2000-05-01 2001-11-12 Targacept, Inc. Imaging of nicotinic acetylcholine receptor subtypes
US6743812B1 (en) 2000-07-14 2004-06-01 Targacept, Inc. Pharmaceutical compositions and methods for use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE62662B1 (en) * 1989-01-06 1995-02-22 Elan Corp Plc Use of nicotine in the treatment of conditions susceptible to said treatment
US5212188A (en) * 1992-03-02 1993-05-18 R. J. Reynolds Tabacco Company Method for treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
JP2001520628A (ja) 2001-10-30
EP0801527A4 (de) 2001-09-05
EP0801527B1 (de) 2006-07-26
DE69535131T2 (de) 2007-03-01
AU4610896A (en) 1996-07-24
DE69535131D1 (de) 2006-09-07
EP0801527A1 (de) 1997-10-22
WO1996020600A1 (en) 1996-07-11
JP3899126B2 (ja) 2007-03-28

Similar Documents

Publication Publication Date Title
ATE334120T1 (de) Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems
DE69532687D1 (de) Pharmazeutische zusammensetzungen zur vorbeugung und behandlung der ulzerativen kolitis
DE69739142D1 (de) Pharmazeutische zusammenstellungen zur prävention und behandlung von zns-erkrankungen
DE602004030222D1 (de) 2-oxo-1,3,5-perhydrotriazapinderivate, die sich zur behandlung von hyperproliferativen, angiogenen und entzündlichen erkrankungen eignen
DE60022050T2 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems
NO961326D0 (no) Inhibitorer av
DE69906671D1 (de) Substituierte 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanone, deren Verwendung zur Behandlung von Erkrankungen des zentralen und periphären Nervensystems und diese enthaltende pharmazeutische Zusammensetzungen
DE69313267T2 (de) 1-alkoxy-2-(alkoxy oder cycloalkoxy)-4-(cyclothioalkyl- oder cyclothioalkenyl)benzole als inhibitoren von cyclischen amp phosphodiesterase und tumornekrosefaktor
DE69413829T2 (de) Antiglucocorticoidsteroide zur behandlung von angststörungen
IL192287A0 (en) Pharmaceutical compositions and methods for use
ATE297396T1 (de) Neue atropisomere von 2,3-disubstituierten-(5,6)- heteroarylkondensierten-pyrimidin-4-onen
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE274496T1 (de) Pharmazeutische zusammensetzungen welche aryl- substituierte olefinische amin-verbindungen enthalten
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
ATE168697T1 (de) Pyrrolidinderivate zur behandlung von cck und gastrin-abhängigen erkrankungen
DE69421705T2 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
ATE172118T1 (de) Verwendung von östriol zur herstellung einen transdermalen therapeutischen systeme zur behandlung von klimakterischer osteoporose
DE69928814D1 (de) Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten
ATE242766T1 (de) Neue derivate von benzoylalkyl-1,2,3,6- tetrahydropyridinen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties